Skip to main content

BeOne Medicines Ltd. (ONC) Stock

BeOne Medicines Ltd. Stock Details, Movements and Public Alerts

Stock Details

BeOne Medicines Ltd. (ONC), a prominent company in the healthcare sector within the biotechnology industry, is based in Switzerland and primarily trades on the NMS.Currently, the stock is trading at $370.87. Over the past 52 weeks, it has ranged between $253.95 and $388.66. This places the current price at 95.4% of its 52-week high and 46.0% above its 52-week low. Recent trading volume was recorded at 354,604. The 14-day Relative Strength Index (RSI) stands at 53.70, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $363.07 by 2.15%. Similarly, it is above its 200-day moving average of $324.35 by 14.34%. The MACD histogram is 1.47, indicating bullish momentum (MACD Line: 5.59, Signal Line: 4.12).

52-Week Range

$388.66 - $253.95

-4.58% from high · +46.04% from low

Avg Daily Volume

376,611

20-day average

100-day avg: 373,000

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

66.35

Above market average

Forward P/E

35.50

Earnings expected to grow

PEG Ratio

0.80

Potentially undervalued

Price to Book

8.10

EV/EBITDA

36.51

EPS (TTM)

$5.59

Price to Sales

6.88

Beta

0.61

Less volatile than market

Q:How is ONC valued relative to its earnings and growth?
BeOne Medicines Ltd. trades at a P/E ratio of 66.35, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 35.50 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.80 suggests the stock may be undervalued relative to its growth rate.
Q:What is ONC's risk profile compared to the market?
With a beta of 0.61, BeOne Medicines Ltd. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 8.10 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

10.70%

Operating Margin

19.06%

EBITDA

$1.07B

Return on Equity

14.66%

Return on Assets

7.46%

Revenue Growth (YoY)

29.60%

Earnings Growth (YoY)

166.70%

Q:How profitable and efficient is ONC's business model?
BeOne Medicines Ltd. achieves a profit margin of 10.70%, meaning it retains $10.70 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 19.06% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 14.66% and ROA at 7.46%, the company achieves moderate returns on invested capital.
Q:What are ONC's recent growth trends?
BeOne Medicines Ltd.'s revenue grew by 29.60% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 166.70% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$42.2B

Revenue (TTM)

$6.13B

Revenue/Share (TTM)

$55.28

Shares Outstanding

104.92M

Book Value/Share

$45.78

Asset Type

EQUITY

Q:What is ONC's market capitalization and position?
BeOne Medicines Ltd. has a market capitalization of $42.2B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 104.92M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does ONC's price compare to its book value?
BeOne Medicines Ltd.'s book value per share is $45.78, while the current stock price is $370.87, resulting in a price-to-book (P/B) ratio of 8.10. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$436.46

17.69% upside potential

Analyst Recommendations

Strong Buy

7

Buy

20

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for ONC?
28 analysts cover ONC with 96% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $436.46 implies 17.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ONC?
Current analyst recommendations:7 Strong Buy, 20 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 27, 2026, 02:11 AM

Technical Indicators

RSI (14-day)

53.70

Neutral

50-Day Moving Average

$363.07

2.15% above MA-50

200-Day Moving Average

$324.35

14.34% above MA-200

MACD Line

5.59

MACD Signal

4.12

MACD Histogram

1.47

Bullish

Q:What does ONC's RSI value tell investors?
The RSI (Relative Strength Index) for ONC is currently 53.70, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret ONC's MACD and moving average crossovers?
MACD analysis shows the MACD line at 5.59 above the signal line at 4.12, with histogram at 1.47. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($363.07) is above the 200-day MA ($324.35), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Oct 27, 2026, 12:52 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for ONC and get notified when the price changes.

Stay Ahead of the Market with BeOne Medicines Ltd. Alerts

Set up price alerts for BeOne Medicines Ltd. and get notified instantly when the price hits your target. Never miss an important price movement again.